Wendy Stock to Antibodies, Monoclonal
This is a "connection" page, showing publications Wendy Stock has written about Antibodies, Monoclonal.
Connection Strength
0.872
-
Burkitt lymphoma/leukemia: improving prognosis. Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S231-8.
Score: 0.206
-
"Dar"-ing to target CD38 in T-ALL. Blood. 2018 03 01; 131(9):948-949.
Score: 0.097
-
Novel drug targets in acute leukemia. Clin Adv Hematol Oncol. 2015 Aug; 13(8):493-5.
Score: 0.081
-
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. Leuk Lymphoma. 2010 Dec; 51(12):2240-9.
Score: 0.058
-
A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia. Leuk Lymphoma. 2009 Dec; 50(12):1958-63.
Score: 0.055
-
Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol. 2009 Dec 20; 27(36):6101-8.
Score: 0.055
-
Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leuk Lymphoma. 2009 Nov; 50(11):1809-17.
Score: 0.055
-
Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. Leuk Lymphoma. 2009 Jan; 50(1):85-91.
Score: 0.052
-
Chimerism does not predict for outcome after alemtuzumab based conditioning. Bone Marrow Transplant. 2007 Jul; 40(2):181.
Score: 0.046
-
A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. Leuk Res. 2006 Jul; 30(7):777-83.
Score: 0.043
-
Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplant. 2006 Feb; 37(3):307-10.
Score: 0.042
-
Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005 Aug 20; 23(24):5728-38.
Score: 0.041
-
High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. Leuk Res. 2011 Mar; 35(3):329-33.
Score: 0.014
-
Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2007 Dec; 40(11):1027-32.
Score: 0.012
-
Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp Hematol. 2001 Feb; 29(2):244-55.
Score: 0.007
-
Biotinylated steroid derivatives as ligands for biospecific interaction analysis with monoclonal antibodies using immunosensor devices. Anal Biochem. 2000 Jul 01; 282(2):173-85.
Score: 0.007